Cancer Family
Retroperitoneal Neoplasm
CI-CAN-00000341Explore in graph →
Non-malignant67 active trials1 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000341Explore in graph →
Clinical trials
299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02302833 | Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study(CABATEN) | completed | Phase 2 | 93 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 |
| Jun 19, 2025 |
| clinicaltrials |
| NCT03370718 | Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT00843037 | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma(SNIPP) | completed | Phase 2 | 25 | University Health Network, TorontoOTHER | 2 | Oct 17, 2024 | clinicaltrials |
| NCT04860700 | The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma | completed | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03008369 | Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05858177 | The Efficacy and Safety of Temozolomide in Patients With MPPGL(MPPGL) | completed | Phase 2 | 62 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT04320589 | the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma | completed | Phase 2 | 30 | National Cancer Institute, EgyptOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01967576 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02468193 | Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2020 | clinicaltrials |
| NCT01635907 | Dovitinib in Neuroendocrine Tumors | completed | Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT01566123 | Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS) | completed | Phase 1 / Phase 2 | 37 | University Hospital HeidelbergOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01833832 | Surgery and Heated Chemotherapy for Adrenocortical Carcinoma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00453895 | Sunitinib in Refractory Adrenocortical Carcinoma(SIRAC) | completed | Phase 2 | 39 | University of WuerzburgOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01413503 | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00028106 | 131MIBG to Treat Malignant Pheochromocytoma | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01514526 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | completed | Phase 2 | 17 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT01152827 | RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid(PheoCarcRAD001) | completed | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT00997594 | Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation | completed | Phase 2 / Phase 3 | 18 | Mie UniversityOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00848016 | Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 7, 2014 | clinicaltrials |
| NCT00002608 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | completed | Phase 2 | 30 | Ottawa Regional Cancer CentreOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01255137 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00071058 | Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2012 | clinicaltrials |
| NCT00324012 | Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma | completed | Phase 2 | 19 | Rigshospitalet, DenmarkOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00454103 | Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy | completed | Phase 1 / Phase 2 | — | University of WuerzburgOTHER | 1 | Aug 18, 2010 | clinicaltrials |
| NCT00001339 | A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2025source: clinicaltrials